Lee K.W.CLord S.JKasherman LMarschner IStockler MGralla RCHIH-HSIN YANGMok TLee C.K.2020-05-262020-05-2620200284-186Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85073982648&doi=10.1080%2f0284186X.2019.1670354&partnerID=40&md5=bccdc6af3ceb43442dde37ef5b831c71https://scholars.lib.ntu.edu.tw/handle/123456789/494875[SDGs]SDG3anaplastic lymphoma kinase; antineoplastic monoclonal antibody; epidermal growth factor receptor; immunological antineoplastic agent; cancer chemotherapy; cancer immunotherapy; disease burden; drug efficacy; ex-smoker; human; Letter; never smoker; overall survival; priority journal; smoking; systematic review; systemic therapy; adverse event; aged; head and neck tumor; immunotherapy; lung tumor; meta analysis; middle aged; non small cell lung cancer; procedures; randomized controlled trial (topic); smoking; treatment outcome; Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Humans; Immunotherapy; Lung Neoplasms; Middle Aged; Randomized Controlled Trials as Topic; Smoking; Squamous Cell Carcinoma of Head and Neck; Treatment Outcomeletter10.1080/0284186X.2019.1670354315527702-s2.0-85073982648